ASCO in ActionASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.

To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.

Tune in to ASCO's new ASCO in Action podcast series, providing analysis and commentary on cancer policy and practice issues, available through iTunes or Google Play.

Showing results for Cancer Research

November 29, 2018

On Nov. 29, ASCO and Friends of Cancer Research applauded the National Cancer Institute’s recent revision of its clinical trial protocol template to broaden eligibility criteria for cancer clinical trials, which went into effect on Nov. 1

November 27, 2018

Over the past two years, the National Cancer Institute (NCI) has worked to implement the Cancer Moonshot Initiative, including recommendations of the Cancer Moonshot Blue Ribbon Panel (BRP) that highlighted 10 areas of cancer research ripe for innovation. 

November 26, 2018

Members of Congress recently introduced bipartisan legislation, H.R. 6836, the CLINICAL TREATMENT Act, which would require Medicaid to cover the routine costs of care for patients with life threatening conditions who are enrolled in clinical trials. ASCO worked closely with Members of Congress to shape the legislation to address this gap in coverage for clinical trials.

November 19, 2018

The ASCO Research Community Forum (RCF) will be hosting a free webinar on Wednesday, December 12, 2018 from 12-1 p.m. ET to share highlights from this year’s RCF Annual Meeting workshop. Participants can gain valuable, actionable resources to implement in their own research programs.

November 9, 2018

Update: ASCO’s resolutions on step therapy, Medicare Part B drugs, a Competitive Acquisition Program (CAP), and clinical trial access were adopted or reaffirmed by the American Medical Association (AMA) House of Delegates, as well as an ASCO-backed resolution on Qualified Clinical Data Registries (QCDRs).

October 30, 2018

Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology (ASCO)’s second annual National Cancer Opinion Survey. This is despite research showing that patients who use alternative therapies instead of standard cancer treatments have much higher mortality rates. The survey also found that amid the ongoing opioid crisis, nearly three in four Americans are opposed to limiting access to opioids for people with cancer, and many cancer patients report difficulty obtaining these medications. In addition, just as many Americans say they are worried about the financial impact of a cancer diagnosis as about dying of cancer, with caregivers and rural Americans bearing the weight of cancer’s financial and access challenges. The National Cancer Opinion Survey is a large, nationally representative survey conducted online by The Harris Poll.

October 24, 2018

ASCO recently submitted two comment letters from ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, to the Food and Drug Administration (FDA) Commissioner Scott Gottlieb related to the modernization of clinical trials.

October 22, 2018

ASCO’s Policy Issue Briefs provide succinct overviews and relevant data on major policy issues impacting patients with cancer and the physicians who care for them. These briefs are designed to be especially helpful for journalists, offering background information on key issues across health policy today.

October 19, 2018

ASCO and the Society for Immunotherapy of Cancer (SITC) have released a joint statement with twelve clinical trial reporting recommendations that address the unique efficacy, toxicity, and combination/sequencing aspects of immuno-oncology (IO) treatments. These recommendations, jointly published in the Journal of Clinical Oncology (JCO) and Journal for ImmunoTherapy of Cancer (JITC), will lead to better IO trial reporting and assessment.

October 18, 2018

Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer of ASCO will moderate a panel at an upcoming public meeting of the Reagan-Udall Foundation for the Food and Drug Administration (FDA) on November 19, 2018, at the FDA main campus at White Oak.

October 2, 2018

ASCO is assembling a cohort of its members who are willing to participate in survey-based research projects of ASCO members for non-commercial purposes. The immense knowledge and experience of ASCO’s membership can help to accelerate the development of new insights and findings that may help to improve care and care delivery.

September 28, 2018

The ASCO Research Community Forum (RCF) 2018 Annual Meeting brought together 159 physician investigators and research staff from 34 states across the country—its largest meeting to-date—to discuss contemporary challenges and develop creative solutions in conducting and managing clinical trials. The meeting, held annually at ASCO's headquarters in the Washington DC Metro area, spanned two days from September 23-24, with a theme of Innovative Solutions. Best Practices. Excellence in Cancer Research.

September 26, 2018

ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.

September 13, 2018

A new study in the Journal of Oncology Practice surveys practices within ASCO’s Quality Oncology Practice Initiative (QOPI®) to learn about real world implementation and use of Patient Reported Outcomes (PROs). The survey yielded valuable information on the perception of PROs among oncology practices and the data currently being collected.

September 13, 2018

The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.

Pages